Blockskye | $15,800,000 | (Jul 18, 2025)
Occupi | $3,000,000 | (Jul 18, 2025)
Receive | $4,000,000 | (Jul 18, 2025)
Certified by Founder
Lodge
Exeliom Biosciences
start up
France
- Dijon, Bourgogne-Franche-Comté
- 21/07/2023
- Series A
- $8,898,320
At Exeliom Biosciences, we develop single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics (also known as Live Biotherapeutics) for the treatment of immune-mediated diseases, with specific focus on inflammatory bowel diseases (IBD), and Crohn’s Disease as a first indication
- Industry Pharmaceutical Manufacturing
- Website https://www.exeliombio.com/
- LinkedIn https://www.linkedin.com/company/nextbiotix/
Related People
Benjamin HadidaFounder
France -
Paris, Île-de-France
Biotech company builder and new therapeutic class explorer
Empirical Security | $12,000,000 | (Jul 18, 2025)
WattCarbon | Undisclosed Amount | (Jul 18, 2025)
StrongestLayer | $5,200,000 | (Jul 18, 2025)
Folio | $14,000,000 | (Jul 18, 2025)
Lo Foods | $3,500,000 | (Jul 18, 2025)
BQP(US) | $5,000,000 | (Jul 18, 2025)
TRIFFT Loyalty | $550,000 | (Jul 18, 2025)
One Biosciences | $17,382,375 | (Jul 17, 2025)
KNOT(INDIA) | $3,000,000 | (Jul 17, 2025)